Xin H Chen

US Patent:

8351672, Jan 8, 2013

Filed:

Sep 26, 2007

Appl. No.:

11/861791

Inventors:

Yang Tao - North Potomac MD, US
Xin Chen - Gaithersburg MD, US
Hansong Jing - Hyatsville MD, US
Bin Zhu - College Park MD, US
Fenghua Jin - Beltsville MD, US

Assignee:

Industry Vision Automation Corp. - Gaithersburg MD

International Classification:

G06K 9/00

US Classification:

382132, 382141, 250370, 250484

Abstract:

A combined X-ray and laser 3D imaging system for food safety inspection, which uses a 3D laser subsystem to get accurate depth information, which is further combined with an x-ray image to achieve accurate physical contamination detection in poultry and other meat products. A unique calibration model is used to calibrate the x-ray and laser 3D imaging systems at the same time. And a nested multi-thread software structure is implemented to prevent data conflict and ensure fully use of system resources during the physical contamination detection of the poultry and other meat products.

US Patent:

20060116325, Jun 1, 2006

Filed:

Feb 15, 2002

Appl. No.:

10/468182

Inventors:

Oleg Chertov - Frederick MD, US
Joost Oppenheim - Bethesda MD, US
Xin Chen - Frederick MD, US
Connor McGrath - Union Bridge MD, US
Raymond Sowder - Frederick MD, US
Jacek Lubkowski - Frederick MD, US
Michele Wetzel - Souderton PA, US
Thomas Rogers - North Wales PA, US

International Classification:

A61K 38/10

US Classification:

514013000, 514014000

Abstract:

Novel methods and compositions are provided for inhibiting interactions between human immunodeficiency viruses (HIVs) and viral coreceptors, including CXCR4 and/or CCR5 coreceptors. The anti-coreceptor binding agent includes a novel peptide portion of the gp120 envelope protein of HIV-1, as well as peptide analogs and mimetics of this peptide, that specifically binds to, or modulates activity of, the coreceptors(s). The anti-coreceptor binding agent is useful as a prophylactic or therapeutic treatment to prevent or inhibit HIV binding to a susceptible cell and thereby reduces infection and/or moderates or treats related diseases. In alternative embodiments, the peptides, analogs and mimetics are effective to inhibit direct co-receptor binding by HIV virus, coreceptor binding by HIV gp120 proteins or peptides, HIV fusion with target host cells, HIV virion entry into host cells, HIV replication, and HIV transmission between cells and hosts. In more detailed embodiments, the anti-coreceptor binding agents of the invention are multi-tropic by exhibiting activity against HIV interactions with multiple, CXCR4 and CCR5, coreceptors.

US Patent:

20060135609, Jun 22, 2006

Filed:

Oct 21, 2005

Appl. No.:

11/255478

Inventors:

Eric Toone - Durham NC, US
David Epstein - Bahama NC, US
Pratap Challa - Durham NC, US
Phillip Snyder - Cambridge MA, US
Xin Chen - Chapel Hill NC, US
Mitchell deLong - Raleigh NC, US

Assignee:

Duke University - Durham NC

International Classification:

A61K 31/225

US Classification:

514547000

Abstract:

The present invention relates generally to ophthamological drugs. More specifically, the inventon relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.

US Patent:

20090318542, Dec 24, 2009

Filed:

Jul 29, 2009

Appl. No.:

12/511861

Inventors:

Eric J. Toone - Durham NC, US
David L. Epstein - Bahama NC, US
Pratap Challa - Durham NC, US
Phillip W. Snyder - Cambridge MA, US
Xin Chen - Chapel Hill NC, US
Mitchell A. deLong - Raleigh NC, US

International Classification:

A61K 31/381
A61K 31/235

US Classification:

514443, 514448, 514545

Abstract:

The present invention relates generally to ophthamological drugs. More specifically, the invention relates to a method of modifying (derivatizing) ophthamological drugs so as to increase their penetration through the cornea. The invention also relates to drugs modified (derivatized) in accordance with the instant method and to the use of same in treating conditions associated with elevated intraocular pressure, particularly, glaucoma.

US Patent:

20110319303, Dec 29, 2011

Filed:

Jun 24, 2011

Appl. No.:

13/168478

Inventors:

Xin Chen - Dallas TX, US
Pranesh B. Aswath - Grapevine TX, US
Ronald L. Elsenbaumer - Arlington TX, US

Assignee:

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

C10M 137/10
C10M 137/06
C10M 147/02
C07F 9/20

US Classification:

508183, 558112, 558202, 508427, 508370

Abstract:

Alkylphosphorofluoridothioates containing alkyl groups of greater than four carbons which exhibit significantly lower wear volume compared to ZDDP, methods of making same with high yields, and methods of using same as lubricant additives.

US Patent:

20130296598, Nov 7, 2013

Filed:

May 6, 2013

Appl. No.:

13/887968

Inventors:

Pranesh Aswath - Grapevine TX, US
Xin Chen - Dallas TX, US
BoHoon Kim - Yongin-si, KR
Ronald L. Elsenbaumer - Arlington TX, US

Assignee:

Board of Regents, The Univeristy of Texas System - Austin TX

International Classification:

C10M 137/10

US Classification:

558129, 558151

Abstract:

Alkylthioperoxydiphosphates having an alkyl group between about 4 and 18 carbons, a decomposition temperature between about 150 and 300 C. and a wear volume between about 0.0025 and 0.0015 mmin HFRB testing, and methods of making same. Lubricant additives that includes the alkylthioperoxydiphosphates.

US Patent:

20130331305, Dec 12, 2013

Filed:

May 7, 2013

Appl. No.:

13/889037

Inventors:

Pranesh Aswath - Grapevine TX, US
Xin Chen - Dallas TX, US
Vibhu Sharma - Arlington TX, US
Maria Amaya Igartua - Eibar, ES
Francesco Pagano - Eibar, ES
Wolfgang Binder - Halle (Saale), ES
Parvin Zare - Halle(Saale), DE
Nicole Doerr - Wiener Neustadt, AT

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C10M 141/10

US Classification:

508388, 508110, 508433, 508427, 508579, 508547

Abstract:

Anti-wear and/or friction reducing formulations that include a mixture of at least one first ionic liquid and at least one ashless antiwear compound. The ashless antiwear compound can be a second ionic liquid or an ashless thiophosphate compound. The formulation desirably provides synergistic anti-wear and/or friction reducing properties. The first IL can be a monocationie ionic liquid or a dicationic ionic liquid. The second IL is a dicationic ionic liquid. The ashless thiophosphate is desirably a thiophosphate, such as a fluorothiophosphate (FTP), an alkylphosphorofluoridothiolate, or an alkylthioperoxydithiophosphate. Antiwear and/or friction reduction formulations comprising the above mixtures diluted up to 25% by weight in a base oil.

US Patent:

20210316012, Oct 14, 2021

Filed:

Aug 9, 2019

Appl. No.:

17/267251

Inventors:

- Chapel Hill NC, US
Xin Chen - Irving TX, US

International Classification:

A61K 48/00
C12N 15/86
A61P 25/00
A61K 31/7088

Abstract:

This invention relates to polynucleotides comprising optimized CLN7 open reading frame (ORF) sequences, viral vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of CLN7, such as variant late infantile neuronal ceroid lipofuscinoses (vLINCL; CLN7 disease).